New MRI technique may slash contrast doses for brain tumor screening

NCT ID NCT04113395

Completed Diagnosis Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 19 times

Summary

This study looked at whether using a much lower dose of gadolinium (a contrast dye) in MRI scans can still reliably detect meningiomas, a common type of brain tumor. Over 500 adults who needed a brain MRI for screening or follow-up took part. The goal is to reduce the amount of gadolinium patients receive, which can build up in the body over time and cause safety concerns.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CHU de Bordeaux

Bordeaux, 33076, France
CHU de Grenoble

Grenoble, Grenoble, 38100, France
CHU de Limoges

Limoges, Limoges, 87042, France
CHU de Lyon

Lyon, Lyon, 69495, France
CHU de Nantes

Nantes, Nantes, 44800, France
CHU de Rennes

Rennes, Rennes, 35033, France
CHU de Rouen

Rouen, Rouen, 76000, France
CHU de Strasbourg

Strasbourg, Strasbourg, 67000, France
CHU de Tours

Tours, Tours, France
Fondation ophtalmique Adolphe de Rothschild

Paris, Paris, 75019, France

Conditions

Explore the condition pages connected to this study.

MENINGIOMA MENINGIOMA